drugset / Trial / NCT04903197
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.
Timeline
- Start
- 2022-01-24
- Primary completion
- 2025-02-24
- Completion
- 2025-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ianalumab | Monoclonal antibody | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |